TWI636978B - １，２，４－二唑苯甲酸之鹽及醫藥組合物 - Google Patents

１，２，４－二唑苯甲酸之鹽及醫藥組合物 Download PDF

Info

Publication number
TWI636978B
TWI636978B TW104107343A TW104107343A TWI636978B TW I636978 B TWI636978 B TW I636978B TW 104107343 A TW104107343 A TW 104107343A TW 104107343 A TW104107343 A TW 104107343A TW I636978 B TWI636978 B TW I636978B
Authority
TW
Taiwan
Prior art keywords
salt
syndrome
compound
crystalline salt
benzoic acid
Prior art date
Application number
TW104107343A
Other languages
English (en)
Chinese (zh)
Other versions
TW201620883A (zh
Inventor
曼達Ｖ 達利
詹姆斯 高杉
瑪拉Ｌ 威托爾
伊簾 威爾區
Original Assignee
美商Ｐｔｃ治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商Ｐｔｃ治療公司 filed Critical 美商Ｐｔｃ治療公司
Publication of TW201620883A publication Critical patent/TW201620883A/zh
Application granted granted Critical
Publication of TWI636978B publication Critical patent/TWI636978B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
TW104107343A 2014-03-06 2015-03-05 １，２，４－二唑苯甲酸之鹽及醫藥組合物 TWI636978B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461949052P 2014-03-06 2014-03-06
US61/949,052 2014-03-06
US201462009111P 2014-06-06 2014-06-06
US62/009,111 2014-06-06

Publications (2)

Publication Number Publication Date
TW201620883A TW201620883A (zh) 2016-06-16
TWI636978B true TWI636978B (zh) 2018-10-01

Family

ID=54055864

Family Applications (2)

Application Number Title Priority Date Filing Date
TW104107343A TWI636978B (zh) 2014-03-06 2015-03-05 １，２，４－二唑苯甲酸之鹽及醫藥組合物
TW107124154A TWI695717B (zh) 2014-03-06 2015-03-05 １,２,４-二唑苯甲酸之鹽及醫藥組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107124154A TWI695717B (zh) 2014-03-06 2015-03-05 １,２,４-二唑苯甲酸之鹽及醫藥組合物

Country Status (10)

Country Link
US (3) US9873677B2 (https=)
EP (1) EP3113619A4 (https=)
JP (3) JP6946001B2 (https=)
KR (2) KR102497273B1 (https=)
CN (3) CN112979575A (https=)
CA (2) CA3174516A1 (https=)
EA (1) EA032779B1 (https=)
IL (1) IL247653B (https=)
TW (2) TWI636978B (https=)
WO (1) WO2015134711A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2402002T (pt) 2005-04-08 2018-10-08 Ptc Therapeutics Inc Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
PL2076501T3 (pl) * 2006-09-25 2016-06-30 Ptc Therapeutics Inc Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego
KR102497273B1 (ko) * 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
JP2018531975A (ja) 2015-10-30 2018-11-01 ピーティーシー セラピューティクス，インコーポレーテッド てんかんの治療方法
US20200262800A1 (en) * 2015-11-16 2020-08-20 Ptc Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
US11135221B2 (en) 2015-12-23 2021-10-05 Moonshot Pharma Llc Methods for inducing an immune response
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
EP3713934B1 (en) 2017-11-23 2022-04-13 Universita' degli Studi di Palermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
CN109678715B (zh) * 2018-11-28 2019-11-12 中国药科大学 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途
US10637694B1 (en) 2018-12-21 2020-04-28 At&T Intellectual Property I, L.P. Reduction and/or mitigation of spatial emissions in multi-antenna wireless communication systems for advanced networks
EP3952867A4 (en) * 2019-04-10 2023-01-11 PTC Therapeutics, Inc. METHODS OF TREATMENT OF NONSENSE MUTATION MEDIATED DUCHENNE MUSCULAR DYSTROPHY IN PEDIATRIC PATIENTS
EP4259097A1 (en) * 2020-12-14 2023-10-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Ataluren eye drop formulation
WO2023205175A1 (en) * 2022-04-18 2023-10-26 Vanderbilt University Polysulfide microparticles and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080114039A1 (en) * 2006-10-12 2008-05-15 Samit Hirawat Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
US7863456B2 (en) * 2006-09-25 2011-01-04 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (https=) 1962-04-17
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4016170A (en) 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4166732A (en) 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4210762A (en) 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
US4268299A (en) 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
US6071700A (en) 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
CZ66498A3 (cs) 1995-09-07 1998-07-15 Novartis Ag Substituované fosfinové kyseliny, způsoby jejich přípravy, farmaceutický prostředek, který je obsahuje, a jejich použití
WO1997041105A1 (en) 1996-04-26 1997-11-06 Nippon Soda Co., Ltd. Novel heterocycle-substituted benzene derivatives and herbicides
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
WO1997046556A1 (en) 1996-06-07 1997-12-11 Merck & Co., Inc. OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
US6034106A (en) 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
DE19626318A1 (de) 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
US6180648B1 (en) 1997-04-07 2001-01-30 Biostream Therapeutics, Inc. Analogs of cocaine
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
AU9647998A (en) 1997-10-27 1999-05-17 Nippon Soda Co., Ltd. Novel benzoylpyrazole derivatives and herbicides
AU750369B2 (en) 1998-04-23 2002-07-18 Cortech, Inc. Cysteine protease inhibitors
WO2000021951A1 (en) 1998-10-08 2000-04-20 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
CA2346396C (en) 1998-10-09 2009-04-28 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
EP1126833A4 (en) 1998-10-29 2004-09-08 Trega Biosciences Inc OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES
KR100630986B1 (ko) 1998-12-23 2006-10-09 스미스클라인 비참 코포레이션 프로테아제 억제제
AU3196300A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
WO2000058278A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives d'acides amines $g(b)
WO2000058304A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
DE60023492T2 (de) 1999-05-17 2006-07-20 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
US6498151B2 (en) 2000-03-22 2002-12-24 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
WO2001083464A1 (en) 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
OA12274A (en) 2000-05-22 2006-05-09 Aventis Pharma Inc Arylmethylamine derivatives for use as tryptase inhibitors.
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
RU2003133750A (ru) 2001-04-19 2005-05-10 Байер АГ (DE) Арилсульфонамиды в качестве антивирусных агентов
JP2005504014A (ja) 2001-06-08 2005-02-10 サイトビア インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法
EP1405636A4 (en) 2001-06-26 2009-04-15 Takeda Pharmaceutical FUNCTIONAL REGULATOR FOR RETINOID RELATIVE RECEPTOR
JP2003081832A (ja) 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
TW200424183A (en) 2002-08-09 2004-11-16 Nps Pharma Inc New compounds
US7074809B2 (en) 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
JP2006521344A (ja) 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
HUE047569T2 (hu) * 2003-04-11 2020-04-28 Ptc Therapeutics Inc 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
JP5255183B2 (ja) * 2003-09-04 2013-08-07 ウォックハート リミテッド ベンゾキノリジン−２−カルボン酸アルギニン塩四水和物
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005097096A1 (en) * 2004-03-31 2005-10-20 Pharmacia & Upjohn Company Llc A phenyl acetic acid cyclooxygenase-2 inhibitor for the treatment of ocular disorders
EP2402323A3 (en) 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
PT2402002T (pt) * 2005-04-08 2018-10-08 Ptc Therapeutics Inc Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
CN101193632A (zh) * 2005-04-08 2008-06-04 Ptc医疗公司 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物
RU2462246C2 (ru) * 2006-03-30 2012-09-27 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
MX2009002439A (es) 2006-09-08 2009-03-27 Ptc Therapeutics Inc Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos.
US8101641B2 (en) 2006-09-25 2012-01-24 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110177999A1 (en) 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
MX2010003612A (es) 2007-10-04 2010-04-30 Merck Serono Sa Derivados de oxadiazol.
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
US8852568B2 (en) 2007-12-17 2014-10-07 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
EP2276763A1 (en) 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
CN102076670B (zh) 2008-06-24 2013-05-22 Irm责任有限公司 调节g蛋白偶联受体的化合物和方法
US8063227B2 (en) 2008-07-14 2011-11-22 Ferrokin Biosciences, Inc. Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
KR101959873B1 (ko) 2008-10-07 2019-03-19 랩터 파마슈티컬스 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
RU2398770C1 (ru) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота
US20120289476A1 (en) 2009-12-11 2012-11-15 Jay Allan Barth Methods for treating methylmalonic acidemia
EP2559443A1 (en) * 2011-08-16 2013-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
WO2014153643A1 (en) * 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
KR102497273B1 (ko) * 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
US20170196842A1 (en) 2014-06-06 2017-07-13 Ptc Therapeutics, Inc. Methods of treatment using a 1,2,4-oxadiazole benzoic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863456B2 (en) * 2006-09-25 2011-01-04 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid
US20080114039A1 (en) * 2006-10-12 2008-05-15 Samit Hirawat Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

Also Published As

Publication number Publication date
US9873677B2 (en) 2018-01-23
CN112979574A (zh) 2021-06-18
IL247653A0 (en) 2016-11-30
US10233161B2 (en) 2019-03-19
KR102497273B1 (ko) 2023-02-07
TW201620883A (zh) 2016-06-16
CA3174516A1 (en) 2015-09-11
JP6946001B2 (ja) 2021-10-06
KR20230024431A (ko) 2023-02-20
US20190152931A1 (en) 2019-05-23
EP3113619A1 (en) 2017-01-11
TW201836605A (zh) 2018-10-16
US20180179170A1 (en) 2018-06-28
CN106455571A (zh) 2017-02-22
CA2942147A1 (en) 2015-09-11
EA032779B1 (ru) 2019-07-31
JP7335795B2 (ja) 2023-08-30
US10618877B2 (en) 2020-04-14
JP2021165299A (ja) 2021-10-14
JP2020045354A (ja) 2020-03-26
IL247653B (en) 2022-04-01
CN112979575A (zh) 2021-06-18
CA2942147C (en) 2022-12-13
EP3113619A4 (en) 2017-09-13
US20170066730A1 (en) 2017-03-09
KR20160122268A (ko) 2016-10-21
WO2015134711A1 (en) 2015-09-11
EA201691789A1 (ru) 2017-02-28
JP2017507158A (ja) 2017-03-16
TWI695717B (zh) 2020-06-11

Similar Documents

Publication Publication Date Title
TWI636978B (zh) １，２，４－二唑苯甲酸之鹽及醫藥組合物
JP7372897B2 (ja) 改善された粘膜輸送を示す医薬用ナノ粒子
JP5315252B2 (ja) 眼科用薬物の輸送に有用なゲル
JP7465453B2 (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
TW200911265A (en) Pharmaceutical compositions and methods of treating dry eye disorders
EA034839B1 (ru) Офтальмологический раствор
CN106999543B (zh) 包含环孢霉素和海藻糖的眼用组合物
CN101005834A (zh) 干眼症治疗用滴眼液
JP2026035663A (ja) 高分子量ヒアルロン酸の眼科用薬物輸送ビヒクルとしての使用
JP2022520410A (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤
BRPI0620080A2 (pt) formulações tópicas de mecamilamina para adminstração ocular e usos das mesma
JP7404658B2 (ja) 涙液層安定化剤及びマイバム分泌促進剤
HK40058574A (en) Pharmaceutical compositions and salts of a 1,2,4- oxadiazole benzoic acid
HK40054075A (en) Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
JP2023536938A (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤
HK1230865A1 (en) Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
RU2853589C2 (ru) Составы на основе 4-(7-гидрокси-2-изопропил-4-оксо-4h-хиназолин-3-ил)-бензонитрила
TW202444380A (zh) 治療白內障手術併發症之方法
Sarvaiya Polymeric Hydrogels for Controlled Drug Delivery to the Eye
GUPTA STUDIES ON IN SITU GELLING SYSTEM FOR BETTER OCULAR DRUG THERAPY
Singh 2³-Factorial Design Studies to Optimize the Ophthalmic Drug Delivery

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees